FDA expands early breast cancer indication for abemaciclib with endocrine therapy

On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER

Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news